Chronic graft versus host disease (cGVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Usage of prophylactic strategies of graft versus host disease (GVHD) before allo-HSCT significantly reduces the incidence of acute GVHD (aGVHD), but it plays a small role in reducing the incidence of cGVHD. At this stage, prophylactic drugs represented by antithymocyte globulin (ATG) can significantly reduce the incidence and severity of cGVHD. Corticosteroids are the first-line treatment of cGVHD. There are many new second-line drug choices for steroid-refractory cGVHD (SR-cGVHD) patients, but there is no first choice for it. The studies of targeted biomarkers of cGVHD will provide a new direction for the treatment of cGVHD in the future. This article summerizes the advances in the prevention, treatment and biomarkers of cGVHD.
